PSMA PET总肿瘤体积预测晚期前列腺癌患者接受[177Lu]Lu-PSMA-617放射性配体治疗的结局:一项双中心分析
该双中心回顾性分析纳入110例接受[177Lu]Lu-PSMA-617放射性配体治疗的晚期前列腺癌患者,基于基线PSMA PET-CT半自动勾画肿瘤病灶,量化病灶数目、PSMA-TV、PSMA-TLU和PSMA-TLQ。结果显示病灶数目、PSMA-TV和PSMA-TLQ均为总生存的预后因素,多因素分析中仅PSMA-TLQ和LDH为独立且显著的负向预后因素。
要点
- PSMA-TV是接受Lu-PSMA治疗患者总生存的显著负向预后因素。
- PSMA-TLQ是独立且优于PSMA-TV的总生存预后因素。
- 多因素分析中PSMA-TLQ和LDH为独立负向预后因素,PSA不显著。
核心结论
- PSMA-TV是接受Lu-PSMA治疗患者总生存的统计学显著负向预后因素。
- PSMA-TLQ是独立且优于PSMA-TV的总生存预后因素。
研究设计与样本
- 来自明斯特和埃森核医学科110例患者的回顾性分析,所有患者均有基线PSMA PET-CT。
- 采用既往发表的方法半自动勾画所有肿瘤病灶,量化病灶数目、PSMA-TV、PSMA-TLU和PSMA-TLQ,回归分析使用Log2转换。
主要发现
- 病灶数目、PSMA-TV和PSMA-TLQ均为总生存的预后因素(HR=1.255,p=0.009;HR=1.299,p=0.005;HR=1.326,p=0.002)。
- 在包含病灶数目、PSMA-TV、PSA、LDH和PSMA-TLQ的逐步后退Cox回归中,仅LDH和PSMA-TLQ保持独立且统计学显著的负向预后因素(HR=1.632,p=0.011;HR=1.239,p=0.024)。
- 多因素Cox回归中PSMA-TLQ和LDH为显著负向预后因素,而PSA值不显著。
关键数值与推荐
- PSMA-TV定义为总肿瘤体积,PSMA-TLU=PSMA-TV×SUVmean,PSMA-TLQ=PSMA-TV/SUVmean。
- 病灶数目HR=1.255(p=0.009),PSMA-TV HR=1.299(p=0.005),PSMA-TLQ HR=1.326(p=0.002)。
- 逐步后退Cox回归中LDH HR=1.632(p=0.011),PSMA-TLQ HR=1.239(p=0.024)。
临床怎么用
- 治疗前PSMA PET衍生的PSMA-TV和PSMA-TLQ可用于识别Lu-PSMA治疗后结局不良风险较高的患者。
- PSMA-TLQ在多因素分析中独立且优于PSMA-TV,可作为预后分层参考指标。
局限性
- 回顾性分析设计。
- 仅纳入两个中心共110例患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: [177Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging treatment option for patients with end-stage prostate cancer. However, response to Lu-PSMA therapy is only achieved in approximately half of patients. It is clinically important to identify patients at risk of poor outcome. Therefore, the aim of this study was to evaluate pretherapeutic PSMA PET derived total tumor volume and related metrics as prognosticators of overall survival in patients receiving Lu-PSMA therapy. METHODS: A total number of 110 patients form the Departments of Nuclear Medicine Münster and Essen were included in this retrospective analysis. Baseline PSMA PET-CT was available for all patients. Employing a previously published approach, all tumor lesions were semi-automatically delineated in PSMA PET-CT acquisitions. Total lesion number, total tumor volume (PSMA-TV), total lesion uptake (PSMA-TLU = PSMA-TV * SUVmean), and total lesion quotient (PSMA-TLQ = PSMA-TV / SUVmean) were quantified for each patient. Log2 transformation was used for regressions. RESULTS: Lesion number, PSMA-TV, and PSMA-TLQ were prognosticators of overall survival (HR = 1.255, p = 0.009; HR = 1.299, p = 0.005; HR = 1.326, p = 0.002). In a stepwise backward Cox regression including lesion number, PSMA-TV, PSA, LDH, and PSMA-TLQ, only the latter two remained independent and statistically significant negative prognosticators of overall survival (HR = 1.632, p = 0.011; HR = 1.239, p = 0.024). PSMA-TLQ and LDH were significant negative prognosticators in multivariate Cox regression in contrast to PSA value. CONCLUSION: PSMA-TV was a statistically significant negative prognosticator of overall survival in patients receiving Lu-PSMA therapy. PSMA-TLQ was an independent and superior prognosticator of overall survival compared with PSMA-TV.
引用
- Seifert R, Kessel K, Schlack K, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2020. PMID: 32970216. doi:10.1007/s00259-020-05040-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。